ExploreWatchlistsPricing
  1. JP-listed companies
  2. Nano Holdings, Inc.
  3. Financials
  4. Cost of revenue

Nano Holdings, Inc. (4571)

Market cap
¥8.4B
P/E ratio
NANO MRNA develops RNA-based drug candidates including mRNA and siRNA therapies, then licenses them to pharmaceutical companies for late-stage development and commercialization.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCost of revenue (Million JPY)YoY (%)
Mar 31, 202621-30.14%
Mar 31, 202530+23.62%
Mar 31, 202425-42.35%
Mar 31, 202343+3.15%
Mar 31, 202241+7.62%
Mar 31, 202138-50.78%
Mar 31, 202078-2.40%
Mar 31, 201980+17.69%
Mar 31, 201868+11.21%
Mar 31, 201761+92.99%
Mar 31, 201632-85.07%
Mar 31, 2015212

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat